InVivo Therapeutics has submitted an updated Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) requesting permission to begin human studies in order to test its biopolymer scaffolding for the treatment of acute SCI.
“We intend to intervene shortly after injury to minimize the advancement of scarring and to provide functional recovery within weeks of treatment.” said Frank Reynolds, InVivo CEO.